MedPath

Sertindole

Generic Name
Sertindole
Drug Type
Small Molecule
Chemical Formula
C24H26ClFN4O
CAS Number
106516-24-9
Unique Ingredient Identifier
GVV4Z879SP
Background

Sertindole, a neuroleptic, is one of the newer antipsychotic medications available. Serdolect is developed by the Danish pharmaceutical company H. Lundbeck. It is a phenylindole derivative used in the treatment of schizophrenia. It was first marketed in 1996 in several European countries before being withdrawn two years later because of numerous cardiac adverse effects. It has once again been approved and should soon be available on the French and Australian market.

Indication

Used in the treatment of schizophrenia.

Associated Conditions
Schizophrenia
Clinical Trials
Related News

Pharmacovigilance in Gerontopsychiatric Patients

Phase 3
Terminated
Conditions
Dementia
Depression
Schizophrenia
Psychosomatic Disorders
Anxiety Disorders
Interventions
First Posted Date
2015-03-02
Last Posted Date
2018-02-28
Lead Sponsor
Hannover Medical School
Target Recruit Count
407
Registration Number
NCT02374567
Locations
🇩🇪

Bezirkskrankenhaus Augsburg, Augsburg, Germany

🇩🇪

Krankenhaus Hedwigshöhe, Berlin, Germany

🇩🇪

Hannover Medical School, Hannover, Germany

and more 2 locations

Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients

First Posted Date
2014-12-04
Last Posted Date
2018-10-11
Lead Sponsor
Technical University of Munich
Target Recruit Count
21
Registration Number
NCT02307396
Locations
🇩🇪

Psychiatrische Klinik und Poliklinik fuer Psychiatrie und Psychotherapie der Technischen Universitaet Muenchen am Klinikum rechts der Isar, Munich, Bavaria, Germany

The Effect of Sertindole and Risperidone on Endophenotypic Markers of Schizophrenia

Phase 4
Terminated
Conditions
Schizophrenia
Interventions
First Posted Date
2013-12-27
Last Posted Date
2020-03-26
Lead Sponsor
Birte Glenthoj
Target Recruit Count
1
Registration Number
NCT02021201
Locations
🇩🇰

Center for Neuropsychiatric Schizophrenia Research, University of Copenhagen, Psychiatric Center Glostrup, Glostrup, Denmark

An Observational Drug Utilization Study of Asenapine in the United Kingdom (P08308)

First Posted Date
2011-12-23
Last Posted Date
2022-02-04
Lead Sponsor
Organon and Co
Target Recruit Count
42
Registration Number
NCT01498770

Comparing the Effects of Sertindole and Olanzapine on Cognition (SEROLA)

Not Applicable
Terminated
Conditions
Schizophrenia
Interventions
First Posted Date
2009-04-22
Last Posted Date
2013-09-04
Lead Sponsor
University of Aarhus
Target Recruit Count
11
Registration Number
NCT00885690
Locations
🇩🇰

Aalborg Psychiatric Hospital, Aalborg, Denmark

🇸🇪

Universitets Allmänna Sjukhuset, Malmø UMAS, Malmø, Sweden

Sertindole in Asian Patients With Schizophrenia

Phase 3
Completed
Conditions
Schizophrenia
Interventions
First Posted Date
2009-03-18
Last Posted Date
2013-09-20
Lead Sponsor
H. Lundbeck A/S
Target Recruit Count
394
Registration Number
NCT00864045
Locations
🇨🇳

CN001, Beijing, China

Safety Study of Sertindole Versus Risperidone Under Normal Conditions of Use

Phase 3
Completed
Conditions
Schizophrenia
Interventions
First Posted Date
2009-03-06
Last Posted Date
2011-08-19
Lead Sponsor
H. Lundbeck A/S
Target Recruit Count
9809
Registration Number
NCT00856583

Safety Study of an Antipsychotic, Sertindole, to Treat Schizophrenia

Phase 4
Completed
Conditions
Schizophrenia
Interventions
First Posted Date
2008-10-01
Last Posted Date
2016-11-08
Lead Sponsor
H. Lundbeck A/S
Target Recruit Count
18
Registration Number
NCT00763438
Locations
🇫🇷

FR002, Allonnes, France

Exploratory Cognition Study of Sertindole in Patients With Schizophrenia

Phase 3
Completed
Conditions
Schizophrenia
Interventions
First Posted Date
2008-09-25
Last Posted Date
2013-09-16
Lead Sponsor
H. Lundbeck A/S
Target Recruit Count
96
Registration Number
NCT00759421
Locations
🇨🇳

TWN001, Tapei, Taiwan

Study on Metabolic Parameters of Sertindole in Patients With Schizophrenia

Phase 3
Completed
Conditions
Schizophrenia
Interventions
First Posted Date
2008-09-25
Last Posted Date
2013-09-20
Lead Sponsor
H. Lundbeck A/S
Target Recruit Count
250
Registration Number
NCT00759460
Locations
🇨🇳

CN002, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy